• Event Type: Earnings Conference Call to discuss unaudited financial results for the quarter and half year ended September 30, 2026 (Q2 FY26-27).
  • Date and Time: The call was held on Monday, November 16, 2026. The specific time and time zone were not disclosed in the provided data.
  • Purpose: Discussion of quarterly results, business updates, strategic initiatives, and future outlook.
  • Earnings Timing: The meeting was held after the earnings announcement, as it discusses already announced Q2 FY27 results.
  • Management Participants:
  • Mr. Manish Grover – Managing Director
  • Mr. Ankush Kaushal – Whole-Time Director
  • Mr. Nanak Chand – Chief Financial Officer
  • Moderator: Ms. Soumya Chhajed from Go India Advisors, LLP
  • Availability of Materials: The transcript of the earnings conference call has been made available on the company's website at: https://jeenasikho.com/wp-content/uploads/2026/11/Jeena-Sikho-Q2FY27-Earning-Call-Transcript.pdf
  • UPSI Statement: The moderator noted that the discussion may include forward-looking statements that must be viewed in conjunction with business risks, but no explicit statement about unpublished price sensitive information was made.

Financial Highlights Discussed

  • Q2 FY27 Performance: Revenue from operations was INR235 crores (up 24% YoY, 5% QoQ), Gross margin was 88%, EBITDA was INR72 crores with 31% margin, PAT was INR36 crores.
  • H1 FY27 Performance: Revenue was INR460 crores (up 26% YoY), EBITDA was INR164 crores with 36% margin, PAT was INR102 crores.
  • Operational Metrics:
  • H1 IPD patients: 22,480 (Q2: 10,980, 14% YoY growth)
  • H1 OPD volume: 3.1 lakh (Q2: 1.59 lakh, 14% YoY growth)
  • Consultation customers: H1 12.1 lakh (Q2: 7.1 lakh, 174% YoY growth)
  • Q2 Occupancy: 55% (H1: 57%)
  • Expense Analysis: Operating expenses rose 83% YoY driven by:
  • Advertisement and promotion expense increased by INR13.4 crores
  • Employee benefit expense increased by INR4.1 crores
  • Other increases in leasehold, courier, and development expenses

Strategic and Business Updates

  • Network Expansion: Currently 62 hospitals, 60 clinics and daycare centers, approximately 2,424 operational beds across 23 states
  • Accreditations: 52 hospitals NABH accredited with 12 more in pipeline
  • New Launches: 10 new products launched in Q2, wellness resort in Himachal Pradesh (108 rooms, 24 villas) launching December 15, 2026
  • Capacity Pipeline: 460 beds in pipeline, with focus on disciplined expansion
  • Strategy Shift: Revised OTC strategy, moving away from high-acquisition cost models to focus on converting product customers to higher-margin Panchakarma services
  • Government Business: Awaiting Ayushman scheme implementation, planning to limit government business to 15% of total revenue

Guidance and Outlook

  • FY27 Guidance: Reaffirmed growth guidance of 20-25% revenue growth and EBITDA margin target of 35-40%
  • H2 Priorities: Increase occupancy on new beds, scale new products and pharmacy channels, disciplined capacity expansion, maintain cash flow quality
  • Long-term Vision: Target of 7,000-10,000 beds in 3-5 years, maintaining 35-40% EBITDA margins at scale

Additional Notes Section

  • Attachments: The regulatory filing indicates the submission of the earnings call transcript to stock exchanges as required by SEBI LODR regulations.
  • Financial Data: The announcement itself did not contain financial data, but the referenced transcript contained extensive financial and operational details from the earnings call.
  • Compliance: The filing was made pursuant to Regulation 30 read with Para A of Part A of Schedule III and Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.